Stay updated with breaking news from Jon Congleton. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
RADNOR, Pa., Jan. 29, 2024 -- Mineralys Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease and other...
RADNOR, Pa., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused o...
Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Get Free Report) CEO Jon Congleton acquired 4,250 shares of the firm’s stock in a transaction dated Wednesday, November 22nd. The shares were purchased at an average cost of $5.97 per share, for a total transaction of $25,372.50. Following the completion of the acquisition, the chief executive officer now directly […]
Operator: Good afternoon, ladies and gentlemen, and welcome to the Mineralys Therapeutics Third Quarter 2023 Conference Call. [Operator Instructions].
Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Get Free Report) has received an average recommendation of “Buy” from the six brokerages that are presently covering the firm, Marketbeat Ratings reports. Six investment analysts have rated the stock with a buy rating. The average 1-year price target among brokers that have covered the stock in the last year […]